dc.contributor | Vall d'Hebron Barcelona Hospital Campus |
dc.contributor.author | Majem Tarruella, Margarita |
dc.contributor.author | Manzano, Jose Luis |
dc.contributor.author | Marquez‑Rodas, I. |
dc.contributor.author | Mujika, K. |
dc.contributor.author | Pérez‑Ruiz, E. |
dc.contributor.author | Muñoz Couselo, Eva |
dc.date.accessioned | 2022-01-25T11:27:29Z |
dc.date.available | 2022-01-25T11:27:29Z |
dc.date.issued | 2021-05 |
dc.identifier.citation | Majem M, Manzano JL, Marquez-Rodas I, Mujika K, Muñoz-Couselo E, Pérez-Ruiz E, et al. SEOM clinical guideline for the management of cutaneous melanoma (2020). Clin Transl Oncol. 2021 May;23:948–960. |
dc.identifier.issn | 1699-3055 |
dc.identifier.uri | https://hdl.handle.net/11351/6887 |
dc.description | Adjuvant treatment; Melanoma; Staging |
dc.description.abstract | Melanoma affects about 6000 patients a year in Spain. A group of medical oncologists from Spanish Society of Medical Oncology (SEOM) and Spanish Multidisciplinary Melanoma Group (GEM) has designed these guidelines to homogenize the management of these patients. The diagnosis must be histological and determination of BRAF status has to be performed in patients with stage ≥ III. Stage I–III resectable melanomas will be treated surgically. In patients with stage III melanoma, adjuvant treatment with immunotherapy or targeted therapy is also recommended. Patients with unresectable or metastatic melanoma will receive treatment with immunotherapy or targeted therapy, the optimal sequence of these treatments remains unclear. Brain metastases require a separate consideration, since, in addition to systemic treatment, they may require local treatment. Patients must be followed up closely to receive or change treatment as soon as their previous clinical condition changes, since multiple therapeutic options are available. |
dc.language.iso | eng |
dc.publisher | Springer |
dc.relation.ispartofseries | Clinical and Translational Oncology;23 |
dc.rights | Attribution 4.0 International |
dc.rights.uri | http://creativecommons.org/licenses/by/4.0/ |
dc.source | Scientia |
dc.subject | Melanoma - Tractament |
dc.subject | Adjuvants immunològics - Ús terapèutic |
dc.subject | Medicina clínica - Presa de decisions |
dc.subject.mesh | Melanoma |
dc.subject.mesh | /therapy |
dc.subject.mesh | Immunotherapy |
dc.subject.mesh | Practice Guideline |
dc.title | SEOM clinical guideline for the management of cutaneous melanoma (2020) |
dc.type | info:eu-repo/semantics/article |
dc.identifier.doi | 10.1007/s12094-020-02539-9 |
dc.subject.decs | melanoma |
dc.subject.decs | /terapia |
dc.subject.decs | inmunoterapia |
dc.subject.decs | guía de práctica clínica |
dc.relation.publishversion | https://doi.org/10.1007/s12094-020-02539-9 |
dc.type.version | info:eu-repo/semantics/publishedVersion |
dc.audience | Professionals |
dc.contributor.organismes | Institut Català de la Salut |
dc.contributor.authoraffiliation | [Majem M] Department of Medical Oncology, Hospital de la Santa Creu i Sant Pau, 08025 Barcelona, Spain. [Manzano JL] Department of Medical Oncology, H. Germans Trias i Pujol, Catalan Institute of Oncology, ICO-Badalona, Badalona, Spain. [Marquez-Rodas I] Department of Medical Oncology, Instituto de Investigación Sanitaria Gregorio Marañón and CIBERONC, Madrid, Spain. [Mujika K] Department of Medical Oncology, UGC de Oncología de Gipuzkoa, OSI Donostialdea-Onkologikoa, Guipúzcoa, Spain. [Muñoz-Couselo E] Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. Servei d’Oncologia Mèdica, Vall d’Hebron Hospital Universitari, Barcelona, Spain. [Pérez-Ruiz E] Department of Medical Oncology, Hospital Costa del Sol and UGC Oncol, Instituto de Investigación Biomédica de Málaga (IBIMA), Hospital Universitario Regional Virgen Victoria, Málaga, Spain |
dc.identifier.pmid | 33651321 |
dc.identifier.wos | 000624437100001 |
dc.rights.accessrights | info:eu-repo/semantics/openAccess |